Drug-induced side effects affecting the gastrointestinal tract

被引:34
作者
Leong, Rupert W. L. [1 ]
Chan, Francis K. L. [1 ]
机构
[1] Univ New S Wales, Lidcombe Hosp, Fac Med, Dept Gastroenterol & Hepatol, Bankstown, NSW 2200, Australia
关键词
aspirin; diaphragm; haemorrhage; NSAID; oesophagitis; perforation; ulcer;
D O I
10.1517/14740338.5.4.585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
With the ever-growing armamentarium of pharmacological agents, the gastrointestinal drug-induced side effects of dyspepsia, nausea, vomiting, diarrhoea and constipation are increasingly seen. They are often self-limiting and without serious sequelae, but of greater concern is drug-induced mucosal ulceration that can manifest as gastrointestinal haemorrhage, stricture and perforation. These complications are mainly attributable to NSAlDs and aspirin, which can injure the mucosa anywhere along the gastrointestinal tract. These iatrogenic serious side effects can be reduced with co-prescription of a proton pump inhibitor, substitution of a COX-2 inhibitor and eradication of Helicobacter pylori when the bacterium is present. Other recognised gastrointestinal complications include small intestinal diaphragm, microscopic colitis, a range of hepatotoxic effects and pancreatitis. The introduction of new classes of drugs has resulted in new adverse effects that require consideration in patients presenting with gastroenterological symptoms. These include pill oesophagitis from bisphosphonates and ischaemic colitis relating to serotonin antagonists. Here, the authors review the literature on drug-induced complications of the gastrointestinal tract and present the pertinent management issues relevant to clinical practice.
引用
收藏
页码:585 / 592
页数:8
相关论文
共 67 条
[1]  
Anderson James G, 2003, Stud Health Technol Inform, V92, P95
[2]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND LIFE THREATENING COMPLICATIONS OF PEPTIC-ULCERATION [J].
ARMSTRONG, CP ;
BLOWER, AL .
GUT, 1987, 28 (05) :527-532
[3]   Octreotide in the management of treatment-related diarrhoea [J].
BaillieJohnson, HR .
ANTI-CANCER DRUGS, 1996, 7 :11-15
[4]   DRUG-INDUCED LYMPHOCYTIC COLITIS [J].
BEAUGERIE, L ;
LUBOINSKI, J ;
BROUSSE, N ;
COSNES, J ;
CHATELET, FP ;
GENDRE, JP ;
LEQUINTREC, Y .
GUT, 1994, 35 (03) :426-428
[5]   Dual acting anti-inflammatory drugs: A reappraisal [J].
Bertolini, A ;
Ottani, A ;
Sandrini, M .
PHARMACOLOGICAL RESEARCH, 2001, 44 (06) :437-450
[6]   Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial [J].
Biancone, L ;
Tosti, C ;
Geremia, A ;
Fina, D ;
Petruzziello, C ;
Emerenziani, S ;
Pallone, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (07) :755-764
[7]   Cholinesterase inhibitors for Alzheimer's disease [J].
Birks, J .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01)
[8]   NABUMETONE - EVIDENCE FOR THE LACK OF ENTEROHEPATIC CIRCULATION OF THE ACTIVE METABOLITE 6-MNA IN HUMANS [J].
BRETT, MA ;
BUSCHER, G ;
ELLRICH, E ;
GREB, WH ;
KURTH, HJ ;
RULANDER, G ;
SCHMERENBECK, B ;
HADDOCK, RE ;
THAWLEY, AR .
DRUGS, 1990, 40 :67-70
[9]   Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding [J].
Chan, FKL ;
Ching, JYL ;
Hung, LCT ;
Wong, VWS ;
Leung, VKS ;
Kung, NNS ;
Hui, AJ ;
Wu, JCY ;
Leung, WK ;
Lee, VWY ;
Lee, KKC ;
Lee, YT ;
Lau, JYW ;
To, KF ;
Chan, HLY ;
Chung, SCS ;
Sung, JJY .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :238-244
[10]   Celecoxib versus diciofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial [J].
Chan, FKL ;
Hung, LCT ;
Suen, BY ;
Wong, VWS ;
Hui, AJ ;
Wu, JCY ;
Leung, WK ;
Lee, YT ;
To, KF ;
Chung, SCS ;
Sung, JJY .
GASTROENTEROLOGY, 2004, 127 (04) :1038-1043